Why Is VOR BIOPHARMA INC (VOR) Stock Down Today?

VOR stock is down 5.78% to $23.65 in morning trading, marking a sharp decline driven by mixed earnings performance and a recent insider sale. The stock opened at $25.02 but quickly moved lower, hitting a session low of $23.59 before settling near that level. The sell-off follows a recent earnings miss and a sale by a top shareholder.

What Happened

Vor Biopharma reported Q2 adjusted earnings per share of $(0.80), missing the estimate of $(0.70). The company also reported a non-GAAP EPS of $(1.16), which fell short of expectations. These results contributed to investor caution. In addition, Ra Capital Management, L.P., a shareholder holding 10% of the company, sold shares on July 16, 2026. The sale is the only insider transaction in the last 90 days, with a total of $4,000 in sales reported. Meanwhile, the company announced the completion of enrollment in its UPSTREAM MG trial, a positive development that did not offset the earnings-related concerns.

What The Data Shows

The stock is trading within its 52-week range of $6.50 to $49.95, having printed nine fresh 52-week lows on September 9, 2026. The session has seen a volume of 0.2 million shares, which is 0.2 times the 3-month daily average. The stock opened at $25.02 and has traded down to $23.59, with the last trade at that level. The market cap is $1.5 billion, and the stock has a P/E ratio of 1.2 and a beta of 1.72, indicating high volatility relative to the market.

What To Watch

Investors should monitor the company’s next earnings report and any further updates on the UPSTREAM MG trial. Coverage breadth remains limited, with only one story published in the last 36 hours.